
Washington ExaminerSig. 6OpinionHealthPoliticsScience
Pancreatic cancer had a 13% survival rate. Trump’s FDA just changed everything
The article praises the FDA's approval of daraxonrasib for advanced pancreatic cancer, crediting the Trump administration's expedited review and priority voucher program. It argues that faster approvals, domestic manufacturing, and MAHA initiatives will bring more cures and strengthen U.S. drug development.










